CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
3.09
1.31%
Market Trading Hours* (UTC) Opens on Monday at 08:00

Mon - Fri: 08:00 - 16:30

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.08
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.022085 %
Charges from full value of position ($-4.20)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.022085%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.000137 %
Charges from full value of position ($-0.03)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.000137%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency EUR
Margin 5%
Stock exchange France
Commission on trade 0%

*Information provided by Capital.com

Valneva SE ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 3.05
Open* 3.05
1-Year Change* -43.93%
Day's Range* 3.02 - 3.14
52 wk Range 3.95-7.85
Average Volume (10 days) 333.04K
Average Volume (3 months) 8.50M
Market Cap 559.06M
P/E Ratio -100.00K
Shares Outstanding 138.77M
Revenue 223.22M
EPS -0.96
Dividend (Yield %) N/A
Beta 0.54
Next Earnings Date Mar 21, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 1, 2024 3.09 0.10 3.34% 2.99 3.14 2.99
Feb 29, 2024 3.05 -0.13 -4.09% 3.18 3.19 3.01
Feb 28, 2024 3.13 -0.01 -0.32% 3.14 3.24 3.12
Feb 27, 2024 3.18 -0.05 -1.55% 3.23 3.24 3.13
Feb 26, 2024 3.20 -0.06 -1.84% 3.26 3.32 3.12
Feb 23, 2024 3.26 -0.07 -2.10% 3.33 3.37 3.20
Feb 22, 2024 3.33 0.05 1.52% 3.28 3.37 3.28
Feb 21, 2024 3.24 0.03 0.93% 3.21 3.27 3.01
Feb 20, 2024 3.27 -0.26 -7.37% 3.53 3.58 3.20
Feb 19, 2024 3.61 -0.05 -1.37% 3.66 3.68 3.58
Feb 16, 2024 3.65 -0.11 -2.93% 3.76 3.78 3.60
Feb 15, 2024 3.76 -0.01 -0.27% 3.77 3.78 3.60
Feb 14, 2024 3.72 0.11 3.05% 3.61 3.72 3.58
Feb 13, 2024 3.68 0.01 0.27% 3.67 3.74 3.66
Feb 12, 2024 3.77 0.19 5.31% 3.58 3.84 3.57
Feb 9, 2024 3.63 0.08 2.25% 3.55 3.74 3.55
Feb 8, 2024 3.72 0.07 1.92% 3.65 3.83 3.65
Feb 7, 2024 3.74 -0.11 -2.86% 3.85 3.90 3.71
Feb 6, 2024 3.78 0.21 5.88% 3.57 3.81 3.47
Feb 5, 2024 3.54 -0.14 -3.80% 3.68 3.79 3.52

Valneva SE Events

Time (UTC) Country Event
Thursday, March 21, 2024

Time (UTC)

10:59

Country

FR

Event

Full Year 2023 Valneva SE Earnings Release
Full Year 2023 Valneva SE Earnings Release

Forecast

-

Previous

-
Tuesday, May 7, 2024

Time (UTC)

06:30

Country

FR

Event

Q1 2024 Valneva SE Earnings Release
Q1 2024 Valneva SE Earnings Release

Forecast

-

Previous

-
Monday, May 13, 2024

Time (UTC)

10:59

Country

FR

Event

Valneva SE German Spring Conference
Valneva SE German Spring Conference

Forecast

-

Previous

-
Wednesday, June 26, 2024

Time (UTC)

10:59

Country

FR

Event

Valneva SE Annual Shareholders Meeting
Valneva SE Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 361.303 348.086 110.321 126.196 113.035
Revenue 361.303 348.086 110.321 126.196 113.035
Cost of Revenue, Total 324.441 182.22 46.902 49.968 44.448
Gross Profit 36.862 165.866 63.419 76.228 68.587
Total Operating Expense 474.746 409.476 165.441 127.007 106.774
Selling/General/Admin. Expenses, Total 56.499 70.761 45.171 42.277 37.84
Research & Development 101.322 168.583 61.354 36.783 24.291
Depreciation / Amortization 4.9 5.4 4.9 4.464 4.331
Unusual Expense (Income) 0.038 5.742 26.41 0.092 0.007
Other Operating Expenses, Total -12.454 -23.23 -19.296 -6.577 -4.143
Operating Income -113.443 -61.39 -55.12 -0.811 6.261
Interest Income (Expense), Net Non-Operating -31.108 -8.281 -10.182 -0.059 -2.909
Other, Net -0.264 -0.308 -0.001
Net Income Before Taxes -144.815 -69.979 -65.302 -0.87 3.351
Net Income After Taxes -143.279 -73.425 -64.393 -1.744 3.263
Net Income Before Extra. Items -143.279 -73.425 -64.393 -1.744 3.263
Net Income -143.279 -73.425 -64.393 -1.744 3.263
Income Available to Common Excl. Extra. Items -143.279 -73.425 -64.393 -1.744 3.264
Income Available to Common Incl. Extra. Items -143.279 -73.425 -64.393 -1.744 3.264
Diluted Net Income -143.279 -73.425 -64.393 -1.744 3.264
Diluted Weighted Average Shares 115.474 97.6193 90.7572 91.7443 81.6002
Diluted EPS Excluding Extraordinary Items -1.24079 -0.75216 -0.70951 -0.01901 0.04
Dividends per Share - Common Stock Primary Issue 0 0 0
Diluted Normalized EPS -1.10971 -0.71392 -0.51936 -0.01836 0.04008
Total Adjustments to Net Income 0.001
Dilution Adjustment 0
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 73.743 33.508 268.079 156.678 93.224
Revenue 73.743 33.508 268.079 156.678 93.224
Cost of Revenue, Total 53.838 20.48 152.962 31.247 171.479
Gross Profit 19.905 13.028 115.117 125.431 -78.255
Total Operating Expense 108.709 50.082 231.112 63.361 243.634
Selling/General/Admin. Expenses, Total 43.261 19.024 33.704 12.488 24.095
Research & Development 25.978 14.065 53.039 23.502 51.883
Other Operating Expenses, Total -14.441 -3.487 -8.585 -3.876 -3.869
Operating Income -34.966 -16.574 36.967 93.317 -150.41
Interest Income (Expense), Net Non-Operating -3.836 -1.673 -12.531 -21.007 -18.577
Other, Net -0.022 -0.029 -0.235
Net Income Before Taxes -38.824 -18.247 24.407 72.31 -169.222
Net Income After Taxes -35.046 -18.127 28.214 72.418 -171.493
Net Income Before Extra. Items -35.046 -18.127 28.214 72.418 -171.493
Net Income -35.046 -18.127 28.214 72.418 -171.493
Income Available to Common Excl. Extra. Items -35.046 -18.127 28.214 72.418 -171.493
Income Available to Common Incl. Extra. Items -35.046 -18.127 28.214 72.418 -171.493
Diluted Net Income -35.046 -18.127 28.214 72.418 -171.493
Diluted Weighted Average Shares 140.184 139.438 122.408 105.991 108.54
Diluted EPS Excluding Extraordinary Items -0.25 -0.13 0.23049 0.68325 -1.58
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.25842 -0.13 0.33638 0.68325 -1.55996
Unusual Expense (Income) 0.073 -0.008 0.046
Total Adjustments to Net Income
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 424.66 585.832 308.427 129.162 125.972
Cash and Short Term Investments 286.532 346.642 204.394 64.439 77.084
Cash 286.533 346.642 173.109 39.439 57.085
Cash & Equivalents -0.001 -0.001
Short Term Investments 31.285 25 20
Total Receivables, Net 23.912 44.013 19.232 24.03 11.259
Accounts Receivable - Trade, Net 23.912 44.013 19.232 24.03 11.259
Total Inventory 35.104 124.098 26.933 25.772 22.727
Other Current Assets, Total 79.112 71.079 57.868 14.921 14.902
Total Assets 621.344 817.352 449.164 264.723 229.907
Property/Plant/Equipment, Total - Net 154.038 173.83 78.153 69.337 37.997
Property/Plant/Equipment, Total - Gross 221.187 215.283 111.31 100.5 75.012
Accumulated Depreciation, Total -67.148 -41.453 -33.156 -31.163 -37.015
Intangibles, Net 28.711 32.7 35.409 41.813 44.891
Other Long Term Assets, Total 13.935 22.866 25.045 22.148 19.925
Total Current Liabilities 277.392 368.979 175.87 41.3 42.944
Accounts Payable 14.505 16.035 24.898 8.868 9.175
Accrued Expenses 42.724 69.333 24.479 18.323 12.793
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 36.991 10.242 9.684 4.307 17.529
Other Current Liabilities, Total 183.172 273.369 116.809 9.802 3.447
Total Liabilities 401.547 646.771 371.742 129.57 86.72
Total Long Term Debt 115.39 104.413 95.767 80.909 40.07
Long Term Debt 87.227 50.726 46.375 24.317 14.272
Capital Lease Obligations 28.163 53.687 49.392 56.592 25.798
Deferred Income Tax 0.694 1.29 0.412
Other Liabilities, Total 8.071 172.089 99.693 7.361 3.706
Total Equity 219.797 170.581 77.422 135.153 143.187
Common Stock 20.755 15.786 13.646 13.642 13.638
Additional Paid-In Capital 594.043 409.258 244.984 297.732 297.72
Retained Earnings (Accumulated Deficit) -389.315 -248.671 -177.835 -170.272 -161.559
Treasury Stock - Common -0.645 -0.645 -0.898 -1.112 -1.133
Other Equity, Total -5.041 -5.147 -2.475 -4.837 -5.479
Total Liabilities & Shareholders’ Equity 621.344 817.352 449.164 264.723 229.907
Total Common Shares Outstanding 138.223 105.115 90.8242 90.8195 90.7935
Total Preferred Shares Outstanding 0.02051 17.8367 17.8367 17.8367 17.8367
Long Term Investments 0 2.124 2.13 2.263 1.122
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 320.653 341.48 389.329 424.66 476.535
Cash and Short Term Investments 171.253 204.411 254.485 286.532 261.042
Cash & Equivalents 171.253 204.411 254.485 -0.001 261.042
Total Receivables, Net 44.346 33.669 27.018 23.912 57.732
Accounts Receivable - Trade, Net 44.346 33.669 27.018 23.912 57.732
Total Inventory 38 33.353 38.999 35.104 96.462
Other Current Assets, Total 67.054 70.047 68.827 79.112 61.299
Total Assets 520.539 542.571 590 621.344 698.083
Property/Plant/Equipment, Total - Net 156.133 156.1 158.039 154.038 170.659
Intangibles, Net 26.341 27.125 27.896 28.711 29.652
Long Term Investments 0 0
Other Long Term Assets, Total 17.412 17.866 14.736 13.935 21.237
Total Current Liabilities 218.151 241.043 263.26 277.392 374.211
Payable/Accrued 94.241 33.52 41.491 74.973
Accrued Expenses 14.496 41.524 15.875 15.738 16.036
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 59.605 47.134 39.944 36.991 15.612
Other Current Liabilities, Total 49.809 108.249 173.921 183.172 267.59
Total Liabilities 363.018 351.864 385.217 401.547 533.1
Total Long Term Debt 134.898 102.098 112.784 115.39 146.007
Long Term Debt 107.047 74.216 83.228 87.227 93.364
Capital Lease Obligations 27.851 27.882 29.556 28.163 52.643
Deferred Income Tax 2.22 0.971 1.057 0.694 1.784
Other Liabilities, Total 7.749 7.752 8.116 8.071 11.098
Total Equity 157.521 190.707 204.783 219.797 164.983
Common Stock 20.837 20.834 20.752 20.755 17.603
Additional Paid-In Capital 594.003 593.96 594.043 594.043 501.638
Retained Earnings (Accumulated Deficit) -457.319 -424.088 -410.011 -389.315 -354.258
Other Equity, Total 0.001 -0.001 -5.041
Total Liabilities & Shareholders’ Equity 520.539 542.571 590 621.344 698.083
Total Common Shares Outstanding 138.772 138.772 138.223 138.223 117.276
Total Preferred Shares Outstanding 0.02051 0.02051 0.02051
Cash 286.533
Short Term Investments
Treasury Stock - Common -0.645
Accounts Payable 44.136
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -143.279 -73.425 -64.393 -1.744 3.264
Cash From Operating Activities -242.445 76.945 137.779 5.529 16.306
Cash From Operating Activities 21.036 14.281 9.799 8.532 6.828
Non-Cash Items -126.058 101.55 116.613 7.769 3.534
Cash Taxes Paid 0.154 1.631 2.021 2.346 1.273
Cash Interest Paid 9.211 8.417 4.711 2.621 4.165
Changes in Working Capital 5.856 34.539 75.76 -9.028 2.68
Cash From Investing Activities -29.054 -93.116 -19.34 -10.685 -2.917
Capital Expenditures -29.322 -93.171 -19.471 -10.884 -3.171
Other Investing Cash Flow Items, Total 0.268 0.055 0.131 0.199 0.254
Cash From Financing Activities 215.116 154.504 21.74 -7.696 30.945
Financing Cash Flow Items -9.211 -8.417 -4.71 -2.621 -4.165
Issuance (Retirement) of Stock, Net 189.837 166.823 0.29 -2.463 49.263
Issuance (Retirement) of Debt, Net 34.49 -3.902 26.16 -2.612 -14.153
Foreign Exchange Effects -0.828 3.96 -0.183 0.207 -0.795
Net Change in Cash -57.211 142.293 139.996 -12.645 43.539
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -18.127 -143.279 -99.075 -171.493 -26.041
Cash From Operating Activities -24.326 -242.445 -186.562 -100.18 -26.806
Non-Cash Items 8.438 -126.058 17.784 -5.481 -6.922
Cash Taxes Paid 0.433 0.154 1.082 0.818 0.318
Cash Interest Paid 2.689 9.211 6.544 4.054 1.909
Changes in Working Capital -14.637 5.856 -105.271 65.641 6.157
Cash From Investing Activities -3.561 -29.054 -22.483 -15.994 -9.447
Capital Expenditures -3.814 -29.322 -22.541 -16.028 -9.461
Other Investing Cash Flow Items, Total 0.253 0.268 0.058 0.034 0.014
Cash From Financing Activities -3.816 215.116 121.631 105.006 0.982
Financing Cash Flow Items -2.689 -9.211 -6.544 -4.054 -1.909
Issuance (Retirement) of Stock, Net -0.194 189.837 93.998 94.308 3.726
Issuance (Retirement) of Debt, Net -0.933 34.49 34.177 14.752 -0.835
Foreign Exchange Effects -0.344 -0.828 1.814 0.751 -0.107
Net Change in Cash -32.047 -57.211 -85.6 -10.417 -35.378
Cash From Operating Activities 21.036 11.153
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Grimaud Family Other Insider Investor 9.51 13209067 0 2023-07-31 LOW
Bpifrance Participations S.A. Sovereign Wealth Fund 9.2164 12801207 1184386 2023-06-20 LOW
CDC Entreprises Valeurs Moyennes Investment Advisor 8.56 11889549 -875049 2023-07-31 LOW
Pfizer Inc Corporation 6.87 9542196 -13890 2023-07-31 LOW
Deep Track Capital LP Hedge Fund 6.55 9097727 -1416746 2023-07-31 MED
Polar Capital LLP Investment Advisor/Hedge Fund 3.6343 5047974 -37561 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.0466 2842624 1025 2023-09-30 LOW
Medical Strategy GmbH Investment Advisor 1.5495 2152225 0 2023-05-31 MED
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 1.4732 2046160 2046160 2022-12-31 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 1.2716 1766167 27679 2023-09-30 LOW
Valneva SE Employees Corporation 0.92 1277849 0 2023-07-31
BlackRock Advisors (UK) Limited Investment Advisor/Hedge Fund 0.2977 413482 -5274 2023-09-30 LOW
HSBC Global Asset Management (France) S.A. Investment Advisor 0.2212 307237 -40571 2022-12-31 LOW
General American Investors Company, Inc. Investment Advisor 0.1607 223201 0 2023-06-30 LOW
Fubon Asset Management Company Ltd. Investment Advisor 0.148 205513 -4390 2023-07-31 MED
ÖKOWORLD LUX S.A. Investment Advisor 0.144 200000 200000 2022-06-30 LOW
AXA Investment Managers Paris Investment Advisor/Hedge Fund 0.1417 196769 0 2023-08-31 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.1395 193740 -372 2023-09-30 LOW
Charles Schwab Investment Management, Inc. Investment Advisor 0.1379 191558 0 2023-09-30 LOW
La Française AM Investment Advisor 0.126 175000 25000 2023-06-30 MED

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Valneva SE Company profile

About Valneva SE

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Financial summary

BRIEF: For the six months ended 30 June 2021, Valneva SE revenues decreased 1% to EUR47.5M. Net loss applicable to common stockholders increased from EUR25.6M to EUR86.4M. Revenues reflect Commercialized Vaccines segment decrease of 22% to EUR31.8M, Canada segment decrease of 75% to EUR2M, United Kingdom segment decrease of 75% to EUR1.1M, Europe excluding France segment decrease of 42% to EUR4.2M.

Equity composition

07/2010, Rights Issue, 2 new shares for every 5 shares held @ EUR 5.06 (Factor: 1.12817). 6/2013, Rights Issue, 5 new shares for every 13 shares held @ EUR2.65 (Factor: 1.11881). 1/2015, Rights Issue, 11 new shares for every 34 shares held @ EUR2.47 (Factor: 1.10896).

Industry: Biotechnology & Medical Research (NEC)

6 rue Alain Bombard
SAINT-HERBLAIN
PAYS DE LA LOIRE 44800
FR

Income Statement

  • Annual
  • Quarterly

News

Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

18:44, 1 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

People also watch

BTC/USD

61,953.80 Price
-1.100% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Gold

2,083.15 Price
+1.890% 1D Chg, %
Long position overnight fee -0.0191%
Short position overnight fee 0.0108%
Overnight fee time 22:00 (UTC)
Spread 0.50

US100

18,286.90 Price
+1.410% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 7.0

XRP/USD

0.64 Price
+5.380% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading